Breaking: FDA’s Latest Betrayal of Public Trust: Approving Nasal Spray Vaccine That’s a Recipe for Disaster
In a move that’s being hailed as a "game-changer" by the pharmaceutical industry, the FDA has greenlit a nasal spray vaccine that can be administered by individuals themselves or their caregivers, without the need for medical supervision. Because, apparently, the public can’t be trusted to use even the simplest of medications responsibly.
FluMist, the nasal spray vaccine developed by AstraZeneca, has been available in healthcare settings since 2003, but its approval for self-administration is a recipe for disaster. The vaccine requires users to fill out a questionnaire on the FlueMist Home website, and once approved by a pharmacist, the nasal spray will be shipped directly to the customer’s door. No medical professional needed.
And the best part? The out-of-pocket cost is a whopping $35 to $45 per dose, which may or may not be covered by insurance. Because, let’s be real, who wouldn’t want to fork over $70 to $90 per year for a vaccine that’s been shown to have similar efficacy to the traditional shot?
The CDC is already singing the praises of FluMist, saying it’s a suitable alternative for people who are averse to getting injections. But what about people who are averse to being treated like cattle and herded into a doctor’s office for a vaccination that’s not even guaranteed to work?
And let’s not forget the WHO’s dire statistics: over a billion cases of seasonal influenza result in 290,000 to 650,000 respiratory deaths each year. So, if the nasal spray vaccine doesn’t work, what then? Will the FDA be responsible for the inevitable death toll?
The FDA’s vaccine center director, Dr. Peter Marks, had this to say: "Today’s approval provides a new option for receiving a safe and effective seasonal influenza vaccine potentially with greater convenience, flexibility and accessibility for individuals and families." Potentially? You mean to say that there are still going to be issues with the vaccine’s efficacy or safety?
The real question is: what’s the motive behind this move? Is it to make a quick buck off the suffering of the public, or is it a genuine attempt to improve public health? Either way, we can’t help but wonder if this is the start of a slippery slope towards further deregulation of the pharmaceutical industry.
Stay vigilant, people. This is not the future we signed up for.
Author: Kayitsi.com
